CADL NASDAQ
Candel Therapeutics, Inc.
1W: -18.7%
1M: -1.2%
3M: +29.3%
YTD: +93.9%
1Y: +117.5%
3Y: +825.4%
5Y: +30.2%
$10.54
-0.79 (-6.93%)
Weekly Expected Move ±11.2%
$8
$9
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$772.6M
52W Range4.35-14
Volume3,595,032
Avg Volume1,706,696
Beta-0.47
Dividend—
Analyst Ratings
Company Info
CEOPaul-Peter Tak
Employees55
SectorHealthcare
IndustryBiotechnology
IPO Date2021-07-27
Websitecandeltx.com
117 Kendrick Street
Needham, MA 02494
US
Needham, MA 02494
US
617 916 5445
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.
Latest News
Candel Therapeutics (NASDAQ:CADL) Shares Up 6.4% Following Analyst Upgrade
CADL Q3 EPS Estimate Reduced by Brookline Capital Markets
Research Analysts Set Expectations for CADL Q3 Earnings
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Tak Paul Peter | S-Sale | 59,379 | $10.46 | 2026-09-11 |
| Tak Paul Peter | S-Sale | 220,866 | $11.50 | 2026-09-10 |
| Zimmermann Martine | A-Award | 64,000 | $12.60 | 2026-09-08 |
| Zimmermann Martine | 0 | — | 2026-09-08 | |
| Tyagarajan Seshu | S-Sale | 7,000 | $12.00 | 2026-08-17 |